Technical Analysis for RPHM - Reneo Pharmaceuticals, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Down | Flat | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Fell Below 20 DMA | Bearish | 0.00% | |
| 50 DMA Support | Bullish | 0.00% | |
| Upper Bollinger Band Touch | Strength | 0.00% | |
| Gapped Down | Weakness | 0.00% | |
| Upper Bollinger Band Touch | Strength | -4.05% | |
| 20 DMA Support | Bullish | -2.92% | |
| Gapped Down | Weakness | -2.92% | |
| NR7 | Range Contraction | -1.19% | |
| Narrow Range Bar | Range Contraction | -1.19% | |
| Upper Bollinger Band Walk | Strength | -1.19% |
| Alert | Time |
|---|---|
| Fell Below 50 DMA | about 19 hours ago |
| 50 DMA Support | about 22 hours ago |
| 60 Minute Opening Range Breakdown | about 22 hours ago |
| Down 3% | about 22 hours ago |
| Fell Below Previous Day's Low | about 22 hours ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/09/2024
Reneo Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California.
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Research Clinical Trial Stage Pharmaceutical Transcription Factors Carboxylic Acids Intracellular Receptors
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Clinical Research Clinical Trial Stage Pharmaceutical Transcription Factors Carboxylic Acids Intracellular Receptors
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 11.295 |
| 52 Week Low | 0.9801 |
| Average Volume | 192,117 |
| 200-Day Moving Average | 4.77 |
| 50-Day Moving Average | 1.66 |
| 20-Day Moving Average | 1.68 |
| 10-Day Moving Average | 1.70 |
| Average True Range | 0.06 |
| RSI (14) | 45.65 |
| ADX | 20.44 |
| +DI | 17.24 |
| -DI | 13.61 |
| Chandelier Exit (Long, 3 ATRs) | 1.57 |
| Chandelier Exit (Short, 3 ATRs) | 1.76 |
| Upper Bollinger Bands | 1.74 |
| Lower Bollinger Band | 1.63 |
| Percent B (%b) | 0.29 |
| BandWidth | 6.65 |
| MACD Line | 0.01 |
| MACD Signal Line | 0.00 |
| MACD Histogram | 0.0029 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.83 | ||||
| Resistance 3 (R3) | 1.84 | 1.79 | 1.80 | ||
| Resistance 2 (R2) | 1.79 | 1.75 | 1.79 | 1.79 | |
| Resistance 1 (R1) | 1.73 | 1.73 | 1.71 | 1.72 | 1.78 |
| Pivot Point | 1.68 | 1.68 | 1.67 | 1.68 | 1.68 |
| Support 1 (S1) | 1.62 | 1.64 | 1.60 | 1.61 | 1.54 |
| Support 2 (S2) | 1.57 | 1.62 | 1.57 | 1.53 | |
| Support 3 (S3) | 1.51 | 1.57 | 1.52 | ||
| Support 4 (S4) | 1.50 |
